鼻咽癌的免疫治疗研究进展

doi:10.11904/j.issn.1002-3070.2021.06.011

Abstract

Abstract: Nasopharyngeal carcinoma is a malignant tumor with a high incidence in southern China.The treatment of nasopharyngeal carcinoma currently uses concurrent radiotherapy and chemotherapy as the main treatment.The prognosis of early nasopharyngeal carcinoma is better,while the prognosis of advanced nasopharyngeal carcinoma is poor.As a new method of treating malignant tumors,immunotherapy is more and more widely used clinically.It has achieved good results in the treatment for some malignant tumors,and has become a current clinical research hotspot.This article reviews the application of immunotherapy in nasopharyngeal carcinoma in order to discover existing problems and new research directions.

Key words: Nasopharyngeal carcinoma, Immunotherapy, Cellular immunotherapy, Monoclonal antibody, Tumor vaccines

CLC Number:

R739.6

YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma[J]. Journal of Practical Oncology, 2021, 35(6): 542-546.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/542

References

1 Cao SM,Simons MJ,Qian CN.The prevalence and prevention of nasopharyngeal carcinoma in China[J].Chin J Cancer,2011,30(2):114-119.
2 卢江岳,张建鑫,葛晓峰.鼻咽癌同步推量同步放化疗与常规分割后缩野同步放化疗的疗效及毒性反应对比分析[J].实用肿瘤学杂志,2020,34(5):440-445.
3 Wu CC,Fang CY,Hsu HY,et al.EBV reactivation as a target of luteolin to repress NPC tumorigenesis[J].Oncotarget,2016,7(14):18999-19017.
4 Le QT,Colevas AD,O′Sullivan B,et al.Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy[J].J Natl Cancer Inst,2019,111(7):655-663.
5 Ma SX,Zhou T,Huang Y,et al.The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma:a systematic review and meta-analysis[J].Ann Transl Med,2018,6(11):201.
6 Eggermont A,Blank CU,Mandala M,et al.Adjuvant pembrolizumab versus placebo in resected stage III melanoma[J].N Engl J Med,2018,378(19):1789-1801.
7 Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J].N Engl J Med,2018,378(22):2078-2092.
8 Motzer RJ,Penkov K,Haanen J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1103-1115.
9 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
10 Holstein SA,Lunning MA.CAR T-cell therapy in hematologic malignancies:a voyage in progress[J].Clin Pharmacol Ther,2020,107(1):112-122.
11 Verdoodt F,Dehlendorff C,Kjaer SK.Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia:a danish nationwide cohort study[J].Clin Infect Dis,2020,70(4):608-614.
12 Stelow EB,Wenig BM.Update From The 4th edition of the World Health Organization classification of head and neck tumours:Nasopharynx[J].Head Neck Pathol,2017,11(1):16-22.
13 Jiang L,Xie C,Lung HL,et al.EBNA1-targeted inhibitors:novel approaches for the treatment of Epstein-Barr virus-associated cancers[J].Theranostics,2018,8(19):5307-5319.
14 Turrini R,Merlo A,Martorelli D,et al.A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors[J].Oncoimmunology,2017,6(4):e1304338.
15 Jain A,Chia WK,Toh HC.Immunotherapy for nasopharyngeal cancer-a review[J].Chin Clin Oncol,2016,5(2):22.
16 Taylor GS,Long HM,Brooks JM,et al.The immunology of Epstein-Barr virus-induced disease[J].Annu Rev Immunol,2015,33:787-821.
17 Fu T,Voo KS,Wang RF.Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo[J].J Clin Invest,2004,114(4):542-550.
18 Gourzones C,Barjon C,Busson P.Host-tumor interactions in nasopharyngeal carcinomas[J].Semin Cancer Biol,2012,22(2):127-136.
19 Chen Y,Chen RJ,Huang XC,et al.Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells[J].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2018,53(12):925-930.
20 Guo X,Zheng H,Luo W,et al.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells[J].Sci Rep,2017,7(1):4859.
21 Huang J,Fogg M,Wirth LJ,et al.Epstein-Barr virus-specific adoptive immunotherapy for recurrent,metastatic nasopharyngeal carcinoma[J].Cancer,2017,123(14):2642-2650.
22 Brown CE,Mackall CL.CAR T cell therapy:inroads to response and resistance[J].Nat Rev Immunol,2019,19(2):73-74.
23 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
24 Larbcharoensub N,Mahaprom K,Jiarpinitnun C,et al.Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma[J].Am J Clin Oncol,2018,41(12):1204-1210.
25 Jiang F,Yu W,Zeng F,et al.PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma[J].BMC Cancer,2019,19(1):503.
26 Huang PY,Guo SS,Zhang Y,et al.Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma[J].Oncotarget,2016,7(11):13060-13068.
27 Wang YQ,Zhang Y,Jiang W,et al.Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis[J].J Immunother Cancer,2019,7(1):298.
28 Ma B,Lim WT,Goh BC,et al.Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma:an international,multicenter study of the mayo clinic phase 2 consortium(NCI-9742)[J].J Clin Oncol,2018,36(14):1412-1418.
29 Fang W,Yang Y,Ma Y,et al.Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials[J].Lancet Oncol,2018,19(10):1338-1350.
30 Wu K,Yi M,Qin S,et al.The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors:a meta-analysis[J].Exp Hematol Oncol,2019,8:26.
31 Zhou S,Khanal S,Zhang H.Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients[J].Ther Clin Risk Manag,2019,15:211-221.
32 Dasari V,Sinha D,Neller MA,et al.Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases:emerging strategies for clinical development[J].Expert Rev Vaccines,2019,18(5):457-474.
33 Taylor GS,Steven NM.Therapeutic vaccination strategies to treat nasopharyngeal carcinoma[J].Chin Clin Oncol,2016,5(2):23.
34 Lin CL,Lo WF,Lee TH,et al.Immunization with Epstein-Barr virus(EBV)peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma[J].Cancer Res,2002,62(23):6952-6958.
35 Si Y,Deng Z,Lan G,et al.The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients:a phase I clinical trial and two-year follow-up[J].Chem Pharm Bull(Tokyo),2016,64(8):1118-1123.
36 Taylor GS,Jia H,Harrington K,et al.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus(EBV)target antigens:a phase I trial in UK patients with EBV-positive cancer[J].Clin Cancer Res,2014,20(19):5009-5022.
37 Wojtak K,Perales-Puchalt A,Weiner DB.Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr virus elicit potent cellular responses and inhibit tumor growth[J].Vaccines(Basel),2019,7(2):44.
38 Kalra M,Gerdemann U,Luu JD,et al.Epstein-Barr virus(EBV)-derived BARF1 encodes CD4-and CD8-restricted epitopes as targets for T-cell immunotherapy[J].Cytotherapy,2019,21(2):212-223.
39 Ahmed M,Lopez-Albaitero A,Pankov D,et al.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies[J].JCI Insight,2018,3(4):e97805.

[1]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[2]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[3]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[4]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[5]	WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(2): 179-183.
[6]	LI Jiaxing,CAO Hui,ZHANG Yu,LI Yong,WANG Zi,JING Chuying,HUANG Limin. Research on the detection of high-frequency mutation genes in ascending and descending nasopharyngeal carcinoma by next-generation sequencing [J]. Journal of Practical Oncology, 2021, 35(1): 28-34.
[7]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[8]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[9]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[10]	LU Jiangyue, ZHANG Jianxin, GE Xiaofeng. A comparative study of the efficacy and toxicity of concurrent bolus chemoradiotherapy and conventional fractionated retroflex field concurrent chemoradiotherapy for nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2020, 34(5): 440-445.
[11]	XIE Yicai,GAO Jianquan. Application value of dynamic contrast enhanced MRI in diagnosis and treatment of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2020, 34(3): 258-261.
[12]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[13]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.
[14]	RUAN Peng, TAN Aili. Predictive value of serum microRNA-127 for chemotherapy resistance in patients with nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 508-512.
[15]	LIU Gengchun, SHEN Liangfang. Relationship between serum long-chain non-coding RNA MALAT1 and AFAP1-AS1,and clinicopathological features and prognosis of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 513-518.

Research progress in immunotherapy of nasopharyngeal carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments